CN109906077A - 依达拉奉与(+)-2-莰醇的舌下用药物组合物 - Google Patents

依达拉奉与(+)-2-莰醇的舌下用药物组合物 Download PDF

Info

Publication number
CN109906077A
CN109906077A CN201780048512.7A CN201780048512A CN109906077A CN 109906077 A CN109906077 A CN 109906077A CN 201780048512 A CN201780048512 A CN 201780048512A CN 109906077 A CN109906077 A CN 109906077A
Authority
CN
China
Prior art keywords
edaravone
baras camphor
pharmaceutical composition
sublingual
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780048512.7A
Other languages
English (en)
Other versions
CN109906077B (zh
Inventor
王毅军
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Ningdan New Drug Technology Co ltd
Beijing Tiantan Hospital
Simcere Pharmaceutical Co Ltd
Original Assignee
Yantai Yenepharma Co ltd
Beijing Tiantan Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yantai Yenepharma Co ltd, Beijing Tiantan Hospital filed Critical Yantai Yenepharma Co ltd
Publication of CN109906077A publication Critical patent/CN109906077A/zh
Application granted granted Critical
Publication of CN109906077B publication Critical patent/CN109906077B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

本发明公开了一种依达拉奉与(+)‑2‑莰醇组合物舌下给药制剂及其制备方法，其中舌下给药制剂包括依达拉奉、(+)2‑莰醇、赋形剂、填充剂、粘合剂、崩解剂、润滑剂等。舌下给药制剂，可以避免肝脏首过效应，样品稳定性好、便于运输、使用方便等优点。

Description

PCT国内申请，说明书已公开。

Claims (11)

  1. PCT国内申请，权利要求书已公开。
CN201780048512.7A 2016-08-29 2017-08-23 依达拉奉与(+)-2-莰醇的舌下用药物组合物 Active CN109906077B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2016107618907 2016-08-29
CN201610761890.7A CN107773545A (zh) 2016-08-29 2016-08-29 依达拉奉与(+)‑2‑莰醇的舌下用药物组合物
PCT/CN2017/098620 WO2018040989A1 (zh) 2016-08-29 2017-08-23 依达拉奉与(+)-2-莰醇的舌下用药物组合物

Publications (2)

Publication Number Publication Date
CN109906077A true CN109906077A (zh) 2019-06-18
CN109906077B CN109906077B (zh) 2020-02-07

Family

ID=61300111

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201610761890.7A Pending CN107773545A (zh) 2016-08-29 2016-08-29 依达拉奉与(+)‑2‑莰醇的舌下用药物组合物
CN201780048512.7A Active CN109906077B (zh) 2016-08-29 2017-08-23 依达拉奉与(+)-2-莰醇的舌下用药物组合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201610761890.7A Pending CN107773545A (zh) 2016-08-29 2016-08-29 依达拉奉与(+)‑2‑莰醇的舌下用药物组合物

Country Status (10)

Country Link
US (1) US11135199B2 (zh)
EP (1) EP3505161B1 (zh)
JP (1) JP6751475B2 (zh)
KR (1) KR102216381B1 (zh)
CN (2) CN107773545A (zh)
AU (1) AU2017317950B2 (zh)
CA (1) CA3037089C (zh)
RU (1) RU2720204C1 (zh)
WO (1) WO2018040989A1 (zh)
ZA (1) ZA201901866B (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022042644A1 (zh) * 2020-08-26 2022-03-03 上海博志研新药物技术有限公司 依达拉奉缓释药物组合物、制备方法及应用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109431966B (zh) * 2018-04-27 2020-09-22 首都医科大学附属北京天坛医院 依达拉奉药物组合物
BR112022000914A2 (pt) * 2019-07-18 2022-03-08 Bdr Pharmaceuticals International Private Ltd Composição farmacêutica
WO2022007831A1 (zh) * 2020-07-08 2022-01-13 先声药业有限公司 一种组合物的医药用途
AU2021329765A1 (en) * 2020-08-17 2023-03-09 Jiangsu Simcere Pharmaceutical Co., Ltd. Stable pharmaceutical composition
CN112426433B (zh) * 2020-12-23 2022-08-05 湖南中医药大学 一种抗脑缺血炎症反应的冰片当归多糖脂质体及制备方法
WO2022192477A1 (en) * 2021-03-10 2022-09-15 Giri Rajan Shobhanath Compounds for treating conditions related to oxidative stress
WO2023078325A1 (zh) * 2021-11-08 2023-05-11 南京宁丹新药技术有限公司 一种含有依达拉奉右莰醇组合物在治疗认知障碍中的应用
WO2024038471A1 (en) * 2022-08-18 2024-02-22 Bdr Pharmaceuticals International Private Limited Oral formulations of edaravone and improved method of manufacturing thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102485223A (zh) * 2010-12-01 2012-06-06 江苏先声药物研究有限公司 一种药物组合物及其在制备治疗脑血管病药物中的应用
CN102579432A (zh) * 2011-01-12 2012-07-18 江苏先声药物研究有限公司 3-甲基-1-苯基-2-吡唑啉-5-酮与2-莰醇组合物的新应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2038696T3 (es) 1986-03-10 1996-07-16 Burghart Kurt Procedimiento para producir un preparado farmaceutico.
IE60601B1 (en) 1986-08-27 1994-07-27 Chugai Pharmaceutical Co Ltd Therapeutic agent for the treatment of disorders associated with cerebral ischemia
KR950010727B1 (ko) * 1993-06-10 1995-09-22 엘지전선주식회사 전력케이블 시험용 단말장치
CN1263472C (zh) 2002-11-29 2006-07-12 张永 一种防治心脑血管疾病的银杏滴丸
CN1739588A (zh) 2005-09-06 2006-03-01 王衡新 一种治疗心血管疾病的中药制剂及其制备方法
CN101524352A (zh) 2008-03-04 2009-09-09 江苏先声药物研究有限公司 一种含有3-甲基-1-苯基-2-吡唑啉-5-酮的组合物
DK3113764T3 (da) 2014-03-04 2020-10-19 Eastgate Pharmaceuticals Inc Farmaceutisk sammensætning til transmukosal afgivelse og fremgangsmåder til behandling af diabetes hos et individ, som har behov derfor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102485223A (zh) * 2010-12-01 2012-06-06 江苏先声药物研究有限公司 一种药物组合物及其在制备治疗脑血管病药物中的应用
CN102579432A (zh) * 2011-01-12 2012-07-18 江苏先声药物研究有限公司 3-甲基-1-苯基-2-吡唑啉-5-酮与2-莰醇组合物的新应用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022042644A1 (zh) * 2020-08-26 2022-03-03 上海博志研新药物技术有限公司 依达拉奉缓释药物组合物、制备方法及应用

Also Published As

Publication number Publication date
CN109906077B (zh) 2020-02-07
JP2019524893A (ja) 2019-09-05
AU2017317950B2 (en) 2019-09-19
CN107773545A (zh) 2018-03-09
EP3505161A1 (en) 2019-07-03
US20200297697A1 (en) 2020-09-24
EP3505161A4 (en) 2020-04-22
JP6751475B2 (ja) 2020-09-02
KR102216381B1 (ko) 2021-02-18
EP3505161B1 (en) 2021-05-12
CA3037089C (en) 2021-02-16
WO2018040989A1 (zh) 2018-03-08
RU2720204C1 (ru) 2020-04-27
CA3037089A1 (en) 2018-03-08
ZA201901866B (en) 2020-10-28
KR20190031316A (ko) 2019-03-25
US11135199B2 (en) 2021-10-05
AU2017317950A1 (en) 2019-02-21

Similar Documents

Publication Publication Date Title
CN109906077A (zh) 依达拉奉与(+)-2-莰醇的舌下用药物组合物
TW518222B (en) Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the preparation of medicines intended to reduce hyperglycaemia
US9782426B2 (en) Anti-viral therapeutic composition
CN109568253A (zh) 液体制剂
CN110520124A (zh) 用于治疗原发性胆汁性胆管炎的化合物和方法
CN104812378B (zh) 固体剂型
CN110368360A (zh) 具有增加的注射速度的阿立哌唑制剂
TW201350137A (zh) 奧氮平口腔速溶膜劑
ES2773834T3 (es) Métodos y composiciones para tratar la depresión usando ciclobenzaprina
WO2024041330A1 (zh) Ly2922470在制备预防或治疗脑血管疾病或组织缺血再灌注损伤药物中的应用
CN109431966A (zh) 依达拉奉药物组合物
TW202228682A (zh) 使用右美托咪啶(dexmedetomidine)鹽酸鹽治療躁鬱症及精神病
CN110123920A (zh) 一种用于治疗失眠症的口腔速溶膜剂及其制备方法
CN113181143B (zh) 一种2-氧代-1-吡咯烷衍生物口溶膜及其制备方法和应用
CN108553428A (zh) 格列本脲制剂及其制备方法
CN110193015A (zh) 一种盐酸伐地那非口腔崩解片及其制备方法
CN101744806B (zh) 松属素外消旋体在制备治疗脑卒中药物中的用途
WO2019158043A1 (zh) 一种稳定的水合氯醛溶液及其制备方法和用途
CN110693882A (zh) 一种舌下用药物组合物
CA3159491A1 (en) Pharmaceutical compositions
JP2021502952A (ja) 間質性膀胱炎の処置方法
BR112021004661A2 (pt) composto, composição farmacêutica, método para tratamento de dor neuropática e/ou prurido, e, uso do composto
CN112773806B (zh) 包含淫羊藿苷元和羟基积雪草酸的药物组合物的医药用途
CN106668865B (zh) 用于治疗脑缺血的药物组合物、制剂及其应用
EP3071202A1 (en) A combination of dosage units for use in the treatment of pre-term labour condition

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20200102

Address after: 264000 No. 2, No. 32 Zhujiang Road, Yantai Economic and Technological Development Zone, Yantai City, Shandong Province

Applicant after: YANTAI YENE BIOMEDICAL TECHNOLOGY Co.,Ltd.

Applicant after: BEIJING TIANTAN HOSPITAL, CAPITAL MEDICAL University

Applicant after: NANJING SIMCERE DONGYUAN PHARMACEUTICA Co.,Ltd.

Address before: 264000 No. 2, No. 32 Zhujiang Road, Yantai Economic and Technological Development Zone, Yantai City, Shandong Province

Applicant before: YANTAI YENE BIOMEDICAL TECHNOLOGY Co.,Ltd.

Applicant before: BEIJING TIANTAN HOSPITAL, CAPITAL MEDICAL University

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant
CP01 Change in the name or title of a patent holder

Address after: 264000 No. 2, No. 32 Zhujiang Road, Yantai Economic and Technological Development Zone, Yantai City, Shandong Province

Co-patentee after: BEIJING TIANTAN HOSPITAL, CAPITAL MEDICAL University

Patentee after: YANTAI YENE BIOMEDICAL TECHNOLOGY Co.,Ltd.

Co-patentee after: SIMCERE PHARMACEUTICAL Co.,Ltd.

Address before: 264000 No. 2, No. 32 Zhujiang Road, Yantai Economic and Technological Development Zone, Yantai City, Shandong Province

Co-patentee before: BEIJING TIANTAN HOSPITAL, CAPITAL MEDICAL University

Patentee before: YANTAI YENE BIOMEDICAL TECHNOLOGY Co.,Ltd.

Co-patentee before: NANJING SIMCERE DONGYUAN PHARMACEUTICA Co.,Ltd.

CP01 Change in the name or title of a patent holder
TR01 Transfer of patent right

Effective date of registration: 20231212

Address after: 210000 l3244, 3 / F, Chuangye building, 1009 Tianyuan East Road, Jiangning District, Nanjing City, Jiangsu Province

Patentee after: Nanjing ningdan new drug Technology Co.,Ltd.

Patentee after: BEIJING TIANTAN HOSPITAL, CAPITAL MEDICAL University

Patentee after: SIMCERE PHARMACEUTICAL Co.,Ltd.

Address before: 264000 No.2, No.32 Zhujiang Road, Yantai Economic and Technological Development Zone, Yantai City, Shandong Province

Patentee before: YANTAI YENE BIOMEDICAL TECHNOLOGY Co.,Ltd.

Patentee before: BEIJING TIANTAN HOSPITAL, CAPITAL MEDICAL University

Patentee before: SIMCERE PHARMACEUTICAL Co.,Ltd.

TR01 Transfer of patent right